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Abstract. Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) are increasingly used in research centers, clinical
trials, and clinical settings. However, their broad-scale use is hampered by lack of standardization across analytical platforms and
by interference from binding of amyloid- (A) to matrix proteins as well as self-aggregation. Here, we report on a matrix effect-
resistant method for the measurement of the AD-associated 42 amino acid species of A (A42), together with A40 and A38
in human CSF based on mass spectrometric quantification using selected reaction monitoring (SRM). Samples were prepared
by solid-phase extraction and quantification was performed using stable-isotope labeled A peptides as internal standards. The
diagnostic performance of the method was evaluated on two independent clinical materials with research volunteers who were
cognitively normal and AD patients with mild to moderate dementia. Analytical characteristics of the method include a lower limit
of quantification of 62.5 pg/mL for A42 and coefficients of variations below 10%. In a pilot study on AD patients and controls,
we verified disease-association with decreased levels of A42 similar to that obtained by ELISA and even better separation was
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obtained using the A42/A40 ratio. The developed assay is sensitive and is not influenced by matrix effects, enabling absolute
quantification of A42, A40, and A38 in CSF, while it retains the ability to distinguish AD patients from controls. We suggest
this SRM-based method for A peptide quantification in human CSF valuable for clinical research and trials.
Keywords: Alzheimer’s disease, amyloid-, cerebrospinal fluid, mass spectrometry, selected reaction monitoring
INTRODUCTION
Alzheimer’s disease (AD), the main cause of
dementia, affects 36 million people worldwide and
is a growing problem in the ageing population [1].
Neuropathologically, the disease is characterized by
distinct changes in the brain including synaptic loss,
aggregation of amyloid- (A) peptides into plaques,
and accumulation of neurofibrillary tangles, consist-
ing of hyperphosphorylated forms of the tau protein
[2]. Since its discovery in plaques, the 42 amino acid
form of A (A42) has been the subject of extensive
research [3]. It is today widely believed that abnormal
accumulation of the peptide in the brain lies at the core
of AD pathogenesis [4].
Cerebrospinal fluid (CSF) abundance of A42 is
approximately 50% lower in AD patients, which
probably reflects sequestration of the peptide in senile
plaques in the brain [5]. Several studies have shown
that the combined measurement of CSF A42 and tau
protein (phosphorylated forms and total concentra-
tions that reflect tangle pathology and cortical axonal
degeneration, respectively) provides high diagnostic
accuracy of AD in cross-sectional case control
studies and longitudinal studies of patients with mild
cognitive impairment [5]. These CSF biomarkers
have been incorporated in novel AD definitions and
diagnostic criteria [6–9] and are increasingly used in
the diagnostic workup at specialized memory clinics
worldwide [5].
Currently, CSF A42 is measured using several
different types of immunoaffinity methods such as
ELISA and newer multiplexed techniques [10]. How-
ever, there is systematic bias in the concentrations
determined using these techniques [11], which to a
large extent depends on differences in assay calibra-
tion and sensitivity to matrix effects. These include
A42-interacting proteins and other factors such as
oligomerization that may influence the fraction of CSF
A42 exposed to the antibodies used for measurements
[12]. An external quality control program, launched
by the Alzheimer’s Association to identify sources of
variability for measurement of A42 [13], concluded
that while intra-laboratory CVs are generally low,
the concentrations reported in different studies vary
considerably, even when the same analytical platform
is used, with mean A42 levels in AD patients in some
studies exceeding those in controls in other studies
[14]. This variation presents a problem for the use of
A42 as biomarker in clinical routine because it is not
possible to establish generally applicable cut-off values
for diagnosis making, and for research because results
from studies performed in different laboratories cannot
be readily compared.
Mass spectrometric quantification of A42 by
selected reaction monitoring (SRM) may overcome
many of the problems associated with antibody-based
quantification methods [15]. A central difference is the
use of stable isotope labeled (heavy) A42 as inter-
nal standard. The heavy peptide is added to the neat
CSF prior to any sample preparation. Being chemically
equivalent to endogenous A42, the heavy peptide has
identical yield through all sample purification steps, as
well as the same ionization efficiency and fragmenta-
tion behavior in the mass spectrometer, and therefore
accounts for any variations in the analytical procedure.
Thereby, quantification is largely unaffected by varia-
tions in the sample preparation. Furthermore, the high
selectivity of detection using SRM alleviates the need
for extensive sample purification. For A38, A40, and
A42, CSF sample preparation can be performed with a
single step of solid-phase extraction (SPE) [16]. Thus,
using SPE allows for quantification of A species
in denatured samples without the need of antibodies.
Most antibody-based methods are influenced by matrix
effects and measure only the so-called free fraction of
A42, i.e., not oligomerized or protein-bound forms, as
revealed by the non-linearity of antibody-based meth-
ods upon dilution of samples [11, 12]. When SPE
is performed under denaturing conditions, for exam-
ple by adding guanidine hydrochloride (GdnHCl),
non-linear dilution effects are much less pronounced
indicating that a larger proportion of the analyte may
be available for quantification (total fraction).
The aim of the current study was to develop a reli-
able SRM-based assay with reduced matrix effect for
quantification of A42, A40, and A38 in human CSF.
The developed assay was evaluated with regards to lin-
earity, coefficient of variation, limit of quantification,
and correlation with an established ELISA method. Its
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diagnostic accuracy was verified in a study of two inde-
pendent clinical materials with 15 AD patients and 15
cognitively normal controls in each set.
MATERIAL AND METHODS
Participants and CSF collection
In the present study we analyzed CSF samples from
15 AD patients, mean age ± SD: 75.6 ± 6.6 years, and
15 healthy controls, mean age ± SD: 66.3 ± 9.8 years.
A second set of CSF samples from 15 AD patients
(mean age ± SD: 81 ± 5.0 years) and 15 healthy
controls (mean age ± SD: 63.9 ± 9.4 years) were ana-
lyzed. All patients have undergone a thorough clinical
investigation, including a medical history, physical,
neurological and psychiatric examination, screening
laboratory tests, and computerized tomography (CT)
of the brain. AD patients fulfilled the DSM-IIIR cri-
teria of dementia [17] and the criteria of probable AD
defined by NINCDS-ADRDA [18]. The control indi-
viduals were cognitively normal research volunteers.
The ethics committee at the University of Lund has
approved analyses of A variants in CSF from AD
patients and controls, and all patients (or their near-
est relatives) and controls gave informed consent for
research, which was conducted according to the provi-
sions of the Helsinki Declaration. The first 10–12 mL
of CSF was collected in polypropylene tubes, gently
mixed to avoid possible gradient effects and aliquoted
in 500L portions in polypropylene cryo tubes. The
CSF samples were stored at −80◦C pending analysis.
Sample preparation
CSF was thawed at room temperature and vor-
texed. A 200L aliquot was transferred to a 1.5 mL
polypropylene tube (LoBind, Eppendorf) containing
200L 5 M GdnHCl for protein denaturation. The
heavy peptide standards (1 mg), A38, A40, and
A42, uniformly labeled with 15N (rPeptide), were dis-
solved in 1 mL of 20% acetonitrile (ACN) and 1%
NH4OH in water, aliquoted and stored at −80◦C in
0.5 mL polypropylene tubes (Eppendorf). Upon anal-
ysis, the internal standards were diluted with 20%
ACN and 1% NH4OH in water to a concentration of
12 nM. GdnHCL treated CSF samples (400L) were
spiked with 8L of the diluted standard and mixed at
room temperature for 45 mins followed by addition of
200L 4% phosphoric acid (H3PO4).
To evaluate if the method is sensitivity to matrix
effects, a CSF pool with an A42 concentration of
1000 pg/mL determined by ELISA was serially diluted
with PBS four times. Four replicates of each dilution
were prepared.
Calibrators
The reverse curve method for calibration was used
to determine the concentrations of unknown sam-
ples as described elsewhere [19]. A pool of human
CSF was spiked with a mixture of heavy labeled
A38, A40, and A42 to final concentrations of
5000 pg/mL, 10000 pg/mL, and 2000 pg/mL, respec-
tively. The spiked CSF samples were serially diluted
(1 : 2) five times with CSF from the same pool (Fig. 1a).
Three replicates of each dilution were analyzed.
The performance of the method including sensitiv-
ity and linearity was evaluated by the reverse curve
method with heavy A38, A40, and A42 peptides
spiked in at 2000 pg/mL and serially diluted down to
62.5 pg/mL.
Intra assay coefficients of variation (CV) were deter-
mined by analyzing 6 separately prepared CSF samples
from one CSF pool (1214 pg/mL) and 6 samples from
another CSF pool (350 pg/mL).
Solid-phase extraction
Extraction of A peptides was performed using
a mixed mode cation exchange SPE 96 well plate
(Oasis MCX Elution, Waters) as described else-
where [16]. Briefly, the plate was washed with 200L
methanol followed by 200L 4% H3PO4 in water
before adding 600L pretreated CSF. After wash-
ing with 200L 4% H3PO4 in water followed by
200L 10% ACN, the samples were eluted with
2×50L 2.5% NH4OH in 75% ACN into 0.75 mL
polypropylene tubes (Micronic). The extracted sam-
ples were dried using vacuum centrifugation and stored
at −80◦C. Prior to analysis the dried samples were dis-
solved in 25L 1% NH4OH in 20% ACN, vortexed
for 30 min at room temperature, and centrifuged briefly
(Fig. 1b).
SRM analysis
Samples (20L) were injected on a reversed-
phase monolith column (ProSwift RP-4 H 1×250 mm,
Thermo Scientific) heated to 50◦C. A 0.2m parti-
cle filter (Waters), which was backflushed between
sample injections, was placed in front of the col-
umn to reduce backpressure build-up. An Accela 1250
pump (Thermo Scientific) was used for delivering the
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Fig. 1. a) Quantification is performed using the reverse curve method for calibration. For the calibration curve, the heavy isotope labeled peptide
is varied while the light (endogenous) peptide is the internal standard (IS). With unknown samples, the heavy peptide is again used as the IS.
b) Overview of the method. For each sample, 200L GdnHCl is added to 200L CSF and IS are spiked in at 2000 pg/mL. The samples are
then mixed in room temperature for 45 minutes and 200L H3PO4 is added to each sample before extraction. Each SPE plate can be loaded
with 96 samples in parallel. The eluted samples are dried simultaneously using vacuum centrifugation (about 45 minutes) and stored in −80◦C.
Prior to analysis the dried samples are redissolved with 25L 1% NH4OH in 20% ACN. The samples are then injected serially on a reversed
phase column which separates the peptides according to their hydrophobicity. Since the shorter A peptides are less hydrophobic than the longer
species, they elute earlier while co-eluting with their corresponding internal standard. The time from injection to injection is 20 minutes. The
A peptides are ionized using electrospray and transmitted through the first quadrupole according to their m/z values to the second quadrupole
which is filled with argon. Here the peptides are fragmented as they collide with the gas atoms and only specific fragments of the A peptides
with predefined m/z values are transmitted through the third quadrupole and further to the detector.
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mobile phases at a flow of 300L/min. Mobile phase A
consisted of 0.1% NH4OH and 5% ACN in water, and
mobile phase B was 0.03% NH4OH in 95% ACN. Elu-
tion was performed using the following linear gradient
steps: t (min.): 0, %B: 0; t: 2, %B: 0; t: 3, %B: 10; t: 10,
%B: 25; t:11, %B: 90, t: 13, %B: 90; t: 14, %B: 0; t: 21,
%B: 0. SRM analysis of positively charged peptide ions
was performed on a triple quadrupole mass spectrome-
ter (TSQ Vantage, Thermo Scientific) with an IonMax
source and HESI-II electrospray probe equipped with
a high-flow metal needle (Thermo Scientific). The
following global MS parameters were used: cone
voltage 3.5 kV; vaporizer temperature 350◦C; sheath
gas pressure 40 psi; auxiliary gas flow 25 (a.u.);
capillary temperature 350◦C; CID gas pressure 1.6
mTorr. Pinpoint software version 1.1 (Thermo Sci-
entific) was used for method optimization and data
processing.
Amino acid analysis
Amino acid analysis was performed for precise
determination of the concentrations of aliquoted
internal standards. Polypropylene vials containing
lyophilized aliquots (12.5g) of the heavy A pep-
tide standards were placed in separate 22 mL glass
vials (Wheaton). Hydrolysis buffer (200L 6 N HCl,
0.1% phenol, 0.1% thioglycol acid) was added to
the bottom of the glass vials. The vials were purged
with argon, closed with a MiniInert valve (Pierce,
p < 5 mbar) and the samples were incubated at 110◦C
for 20 h. The dried samples were redissolved in 70L
loading buffer (pH 2.2) containing 1 nmol NorLeu
and half the sample was applied to a BioChrom
31 amino acid analyzer running the sodium accel-
erated buffer system. The analyzer was calibrated
to an r2 value >0.999 and for every 6th sample a
1600 pmol standard was analyzed for recalibration.
After analysis, integration of the chromatograms were
checked manually and the integration results were
analyzed using an in-house developed program AAA
ver. 1.03, which corrects for intensity changes of
the ninhydrin (−3.9%) and performs a best linear
fit of hydrolysis data to the theoretical sequence
(∼+1%).
Statistics
All statistical calculations were performed using
Graphpad (version 5.02) software. For the AD versus
control comparisons, the Mann-Whitney U-test was
used. Linear regression was used for analyses of corre-
lation between methods. Estimates of diagnostic accu-
racy were sensitivity, specificity, and the area under
the receiver operating characteristics curve (AUROC).
p < 0.05 was considered statistically significant.
RESULTS
Optimal transitions for A38, A40, and A42 were
determined through direct infusion of each peptide sep-
arately into the mass spectrometer. The most prominent
precursor charge state for each of the three peptides
was selected by manual evaluation of the full scan tan-
dem mass spectrometry (MS/MS) spectra (Fig. 2a–c).
For each precursor, the top 10 most prominent product
ions were used for further optimization by system-
atically varying collision energy and collision gas
pressure. The three best transitions were selected for
each peptide and used for quantification (Table 1).
The LC gradient was optimized for a short analysis
time (20 min in total including washing and equili-
bration of the column) and sufficient separation for
implementation of the scheduled SRM. Typical SRM
chromatograms for A42, A40, and A38 in a human
CSF sample are shown in Fig. 2d.
Analytical characteristics of the method includes
linear results upon serial dilution of CSF (Fig. 3) and a
lower limit of quantification (LLOQ) for A38, A40,
and A42 was determined to 250 pg/mL, 62.5 pg/mL,
and 62.5 pg/mL, respectively, with CVs of 11%, 13%,
and 5% (Fig. 4). For A42, intra-assay CVs were 12%
at 350 pg/mL and 6% at 1214 pg/mL, respectively.
The influence of GdnHCl on the levels of A42 mea-
sured was tested by varying the amount of GdnHCl
added to the CSF (2.5 and 6 M final concentrations).
No significant difference was observed (<5%).
To test the ability of the SRM assay to separate
AD patients from controls, we determined the con-
centrations of A38, A40, and A42 in two sets of
15 AD and 15 control CSF samples. Aliquots of the
samples were, in parallel, analyzed by A42 ELISA.
A human CSF pool were analyzed every 10 samples to
monitor the stability of the method. Even though the
CSF A42 concentration obtained by SRM yielded an
approximately two-fold higher absolute concentration
compared to values obtained with ELISA, there was a
statistically significant linear correlation between SRM
and ELISA A42 (Fig. 5a and 6a), with an R2 value of
0.35 (p < 0.0001) for set one and an R2 value of 0.77
(p < 0.0001) for set two. The separation between AD
patients and controls was similar using SRM with a
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Fig. 2. MS/MS spectra for A38, A40, and A42. Transitions used for the assay are marked with corresponding ion type and charge state
for A38 (a), A40 (b), and A42 (c). Typical SRM chromatograms for A38, A40, and A42 (d). Absolute concentration of endogenous A
peptide is calculated using the area ratio for the co-eluting internal standard of known concentration.
sensitivity of 93% and specificity of 80% compared to
ELISA (Fig. 5b, c) and a sensitivity and specificity of
86.7% for set two (6b, c). The ratio of A42 to A40
(A42/A40) further improved the separation between
the diagnostic groups (Fig. 5d, e and 6d, e).
DISCUSSION
We here report on the development of an antibody-
independent, matrix effect resistant assay for quantifi-
cation of A42, A40, and A38 using SRM-based
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Table 1
Transitions used in the SRM assay. Internal heavy standards are marked with asterisk
Peptide Precursor ion charge state Precursor ion m/za Product ion charge state Product ion Product ion m/z Collision Energy (eV)
1–38 4+ 1033.897 4+ b34 943.286 22
1–38∗ 4+ 1045.927 4+ b34 954.392 22
1–38 4+ 1033.897 4+ b35 976.085 21
1–38∗ 4+ 1045.927 4+ b35 987.400 21
1–38 4+ 1033.897 4+ b36 1000.868 20
1–38∗ 4+ 1045.927 4+ b36 1012.416 20
1–40 4+ 1083.463 4+ b38 1029.180 23
1–40∗ 4+ 1096.626 4+ b38 1042.059 23
1–40 4+ 1083.463 4+ b39 1053.960 20
1–40∗ 4+ 1096.626 4+ b39 1067.091 20
1–40 4+ 1083.463 3+ b32 1200.500 22
1–40∗ 4+ 1096.626 3+ b32 1215.543 22
1–42 4+ 1129.522 4+ b39 1057.177 22
1–42∗ 4+ 1143.182 4+ b39 1067.091 22
1–42 4+ 1129.522 4+ b40 1078.740 21
1–42∗ 4+ 1143.182 4+ b40 1092.122 21
1–42 4+ 1129.522 4+ b41 1107.000 20
1–42∗ 4+ 1143.182 4+ b41 1120.660 20
am/z = mass to charge ratio.
Fig. 3. Linearity of A42 measured by SRM (area ratio light/heavy)
of human pool-CSF, with a concentration of 1000 pg/mL measured
by ELISA, serially diluted with PBS four times.
mass spectrometry. The performance of the method
was evaluated in two independent AD and control stud-
ies which showed statistically significant correlations
to ELISA measurements of A42 as well as similar
separations between the groups indicating that SRM-
based mass spectrometry can be used as a clinically
useful assay for measurement of A42 in human CSF.
For A, previous studies have shown that while
there is no significant change in the CSF A40
concentration between AD and controls, there is
already a decrease in the A42/A40 in the mild cog-
nitive impairment stage of AD. This decrease is more
pronounced than the reduction in CSF A42 alone
[20, 21]. Using SRM-based quantification of A42
and A40, we here replicate the finding that the CSF
A42/A40 ratio increases the separation performance
between AD and controls as compared to A42 alone.
Further studies will be aimed to elucidate whether the
ratio is a prognostic AD marker which can be used for
AD diagnosis already at the pre-symptomatic stage of
the disease.
An important advantage over immunoassays is the
ability to include additional peptides such as other iso-
forms of Aor other endogenous peptides to an already
existing SRM assay to assemble a panel of biomark-
ers tailored to specific clinical questions which can be
analyzed in a single run.
Several studies suggest that A-binding proteins
may have an impact on the measured concentration of
A42 since there might be a difference in free A42
and total A42 in CSF [11, 12]. Recently, it was shown
that denaturation of proteins in CSF with GdnHCl
before analysis resulted in increased concentration
of A42 by ELISA [12]. In the present study, using
GdnHCl in the sample purification, the CSF A42
concentrations obtained with the SRM assay were
approximately twice as high as the concentrations
determined by ELISA, while the separation between
AD patients and controls remained in spite of the
denaturing conditions. Furthermore, increasing the
amount of GdnHCl added to the CSF did not increase
the free A42 measured in our study.
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Fig. 4. Calibration curves with the SRM peak areas as a function of the peptide concentration for A42 (a), A40 (b), and A38 (c).
There are several aspects to consider including high
specificity as well as robustness and stability of the
method when analyzing large series of samples. While
SPE purification in the 96-well format is performed
in parallel with many samples, the subsequent LC-MS
analysis is serial. Thus, the extracted samples will have
different time delay for LC-MS. Using the described
SRM method, dried extracted samples were analyzed
after being stored in freezer (−20◦C) for four months
with minimal loss in signal (less than 1%).
A matrix effect-resistant A42 method is important
to reduce the bias in CSF A42 measurements between
commercially available assays. An essential compo-
nent of such a method is that, e.g., the calibration of
the method is performed in a matrix is identical to
the sample-matrix to be analyzed. To achieve a matrix
effect-resistant method, we used the reverse curve
method for calibration which previously has been
shown to give equal or better trueness and precision
compared to traditional calibration curves or single
reference point calibration [19]. For a reverse curve
calibration, the heavy peptide is varied while the
light (endogenous) peptide is the internal standard
and is held constant. With unknown samples, the
heavy peptide is again used as the internal standard
by adding at a fixed amount to the samples, and
the light amount is measured by reverse-calculating
against the calibration curve. The method also works
with calibration in artificial CSF and gives similar
quantitation results as the reversed curve method in
human CSF. The latter method was chosen because
it avoids the risk of matrix effects that may distort
results when constructing a calibration curve in a
matrix different from that of the unknowns.
SRM-based quantification of A40 and A42 in
human AD and control CSF was first reported by Oe
et al. [22]. Their method relied on antibodies for sam-
ple purification, followed by LC-MS in a basic buffer
system, and the authors showed higher concentrations
of CSF A42 obtained with SRM compared to ELISA,
which is in agreement with this study [22]. However,
electrospray was performed in the negative ion mode,
resulting in low efficiency of fragmentation, and only
one transition per peptide was used for quantification,
which may make the assay vulnerable to interference
from other sample components (cross-talk) [23]. The
current practice is to select two or more transitions per
peptide for reliable quantification [24]. Furthermore,
the transition chosen was neutral loss of H2O. While
sensitive, this is a non-peptide-specific loss, which
increases the risk of cross-talk. In a further devel-
opment, Lame et al. showed that antibody-dependent
enrichment of CSF A38, A40, and A42 could be
replaced by SPE without loss of detection sensitivity
or precision. They also demonstrated that while using
a basic buffer system, operating the mass spectrome-
ter in the positive ion mode resulted in lower detection
sensitivity compared to negative mode. This approach
was still preferable because of increased selectivity for
A peptides together with increased stability of the A
signal [16]. They did not perform AD-control compar-
isons to test the diagnostic accuracy of the method.
To achieve high specificity and stability over time,
we analyzed the samples in the positive ion mode,
and monitored three b ions per peptide using sched-
uled SRM, thereby reducing the signal-to-noise ratio
while the limit of detection was improved [25]. With
the one-step SPE procedure described here, the A
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Fig. 5. Set one of 15 AD patients and 15 controls. Correlation between SRM A42 and ELISA A42 assays (a). Separation of AD and control
groups for ELISA A42 (p < 0.0001) (b) and SRM A42 (p = 0.0011) (c) and separation of AD and control groups for SRM using the A42/A40
ratio (p < 0.0001) (d). The solid line represents median value for each group while the dashed line represents the optimal sensitivity and specificity
for separation of AD and control groups. The sensitivity and specificity of the different methods is summarized in an ROC curve, AUC ELISA
A42 = 0.92, SRM A42 = 0.85, SRM A42/A40 = 0.97 (e).
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Fig. 6. Set two of 15 AD patients and 15 controls. Correlation between SRM A42 and ELISA A42 assays (a). Separation of AD and control
groups for ELISA A42 (p = 0.0004) (b) and SRM A42 (p = 0.0004) (c) and separation of AD and control groups for SRM using the A42/A40
ratio (p = 0.0002) (d). The solid line represents median value for each group while the dashed line represents the optimal sensitivity and specificity
for separation of AD and control groups. The sensitivity and specificity of the different methods is summarized in an ROC curve, AUC ELISA
A42 = 0.88, SRM A42 = 0.88, SRM A42/A40 = 0.91 (e).
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samples loaded on the LC-MS system are quite crude,
containing many other peptides and larger proteins, as
well as aggregates and particles. These sample impuri-
ties may contaminate the system and cause degradation
of the analytical performance over time. Trapping of
insoluble materials on the particle filter resulted in
successively increased back pressure over the filter.
By implementing a routine for backflushing the filter
between sample injections, the trapped particles were
removed, and minimal pressure build-up over the filter
was observed.
When using a silica-based C18 column for pep-
tide separation, as described in previous studies [16,
22, 26], we noticed a gradual back pressure build-up
over the separation column following each consecutive
sample injection. This is most likely caused by irre-
versible binding of sample impurities to the column
and resulted in the column needing to be replaced after
less than 10 injections. This may have severe impli-
cations for the applicability of the method to routine
work: it increases the cost per sample by over $100 and
causes down-time because each new column has to be
tested before use. We therefore evaluated the use of a
monolith separation column based on a polystyrene
divinylbenzene copolymer bed. Possessing weaker
hydrophobic retention characteristics than particle-
based C18 stationary phases, this chromatographic
medium is less prone to contamination by proteins and
other hydrophobic molecules. The separation column
used in this study has been used for over 200 injections
of human CSF samples without any increase in back
pressure or degradation of performance.
While SRM has been used for over three decades,
its main area of application has been small-molecule
analysis, and only in recent years has the technique
emerged as an alternative to immunoassays for pro-
tein and peptide quantification [27]. In this respect, the
technique has distinct advantages. For one, molecular
mass-based selective quantification allows one to dis-
criminate between modified forms of a target molecule,
which would be indistinguishable in an immunoassay.
Assay development is generally quicker and panels of
many target molecules can be assayed in one analysis.
For A42, it is plausible that SRM-based assays will
overcome the problem of inter-laboratory variation
discussed above, because mass spectrometric quantifi-
cation using stable isotope-labeled internal standards
enables absolute quantification and is uninfluenced
by matrix effects. This notion is currently being
evaluated in a collaborative effort involving several
research laboratories within the Global Consortium for
Biomarker Standardization (GCBS) of the Alzheimer’s
Association. A positive evaluation, however, does not
necessarily imply that SRM assays will likely replace
immunoassays in clinical routine in the near future;
LC-MS analysis is a serial, relatively time-consuming
process that cannot match the sample throughput of
state-of-the-art immunoassay methods. A more likely
scenario is that SRM will be used as a reference
technique to determine the absolute A42 levels in
reference materials. Such materials have been used as
‘gold standards’ in other areas of laboratory medicine
to reduce measurement variability and harmonize ana-
lytical results obtained in different laboratories [28].
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